Prostate highlights from ECC 2015

Share :
Published: 27 Sep 2015
Views: 3501
Rating:
Save
Prof Noel Clarke and Dr Bertrand Tombal

Prof Noel Clarke (The Christie Hospital, Manchester, UK) and Dr Bertrand Tombal (Saint-Luc Hospital, Brussels, Belgium) discuss the evolving treatment landscape in prostate cancer for ecancertv at ECC 2015, with a particular focus on new data and dialogue arising from the conference.

They first comment on the potential of TAK-385, a new oral gonadotropin-releasing hormone antagonist. Phase II study findings presented at the meeting showed that it had a good efficacy and safety profile and might thus offer an alternative to existing GnRH androgen deprivation therapies that currently have to be injected.

They also discuss new findings on neoadjuvant therapy for patients undergoing prostatectomy and the results of the STAMPEDE trial. The STAMPEDE trial looked at using docetaxel, zoledronic acid, or both, versus standard of care for hormone-naïve, high-risk, localized or metastatic prostate cancer.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).